LAFAYETTE, La., June 13, 2023 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ:VMD and TSX:VMD.TO), a national leader in respiratory care and technology-enabled home medical equipment services, today announced the voting results from its annual general meeting of shareholders held on June 13, 2023 (the “Meeting”) in Lafayette, Louisiana. The total number of shares represented in person or by proxy at the Meeting was 27,309,147, representing 71.33% of the total issued and outstanding shares in the capital of the Company.
Election of Directors
The eight candidates nominated for election to the Company’s Board of Directors (the “Board”) and listed in the Company’s management information and proxy circular dated April 28, 2023 (the “Circular”), were elected by at least a majority of the shareholders present in person or represented by proxy at the Meeting. The voting results are as follows:
Name | Votes For | % For | Votes Withheld | % Withheld | ||||
Casey Hoyt | 22,064,219 | 94.49% | 1,287,267 | 5.51% | ||||
W. Todd Zehnder | 21,838,919 | 93.52% | 1,512,567 | 6.48% | ||||
William Frazier | 21,849,426 | 93.57% | 1,502,060 | 6.43% | ||||
Randy Dobbs | 22,708,754 | 97.25% | 642,732 | 2.75% | ||||
Nitin Kaushal | 13,154,410 | 56.33% | 10,197,076 | 43.67% | ||||
Timothy Smokoff | 21,960,150 | 94.04% | 1,391,336 | 5.96% | ||||
Bruce Greenstein | 21,219,374 | 90.87% | 2,132,112 | 9.13% | ||||
Sabrina Heltz | 21,959,192 | 94.04% | 1,392,294 | 5.96% |
Appointment of Auditors
The Company’s shareholders have approved the appointment of Ernst & Young LLP as the auditor of the Company for the fiscal year ended December 31, 2023 and authorized the Board to fix the auditor’s remuneration.
ABOUT VIEMED HEALTHCARE, INC.
Viemed is a provider of in-home medical equipment and post-acute respiratory healthcare services in the United States. Viemed’s service offerings are focused on effective in-home treatment with clinical practitioners providing therapy and counseling to patients in their homes using cutting-edge technology. Visit our website at www.viemed.com.
For further information, please contact:
Glen Akselrod
Bristol Capital
905-326-1888
This email address is being protected from spambots. You need JavaScript enabled to view it.
Todd Zehnder
Chief Operating Officer
Viemed Healthcare, Inc.
337-504-3802
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$6.61 |
Daily Change: | -0.27 -3.92 |
Daily Volume: | 197,980 |
Market Cap: | US$257.390M |
March 10, 2025 November 06, 2024 April 02, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load